Clinical Trial Update: Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial evaluating secondary cytoreduction followed by hyperthermic intraperitoneal chemotherapy for ovarian cancer patients resist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PARP inhibitors

Snippet

Sponsor: Fudan University | Conditions: Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING